Media stories about AveXis (NASDAQ:AVXS) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6265514818788 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of AveXis (AVXS) opened at 88.08 on Friday. The stock’s market capitalization is $2.81 billion. AveXis has a 1-year low of $38.46 and a 1-year high of $99.45. The stock’s 50 day moving average price is $93.12 and its 200-day moving average price is $80.06.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($1.10). During the same quarter in the prior year, the company posted ($0.68) earnings per share. Equities research analysts anticipate that AveXis will post ($6.04) EPS for the current fiscal year.
Several brokerages recently weighed in on AVXS. Citigroup Inc. began coverage on AveXis in a research note on Tuesday, May 23rd. They set a “buy” rating and a $90.00 target price for the company. Nomura assumed coverage on AveXis in a research note on Monday, August 28th. They set a “reduce” rating and a $52.00 target price for the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, May 25th. Instinet assumed coverage on AveXis in a report on Tuesday, August 29th. They set a “reduce” rating and a $52.00 target price for the company. Finally, Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $99.29.
In other news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total value of $145,746.40. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $145,746.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 5,340 shares of company stock valued at $474,637 over the last quarter. 18.60% of the stock is owned by corporate insiders.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.